(ACT) AlzChem - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A2YNT30
ACT EPS (Earnings per Share)
ACT Revenue
ACT: Specialty Chemicals, Calcium Cyanamide, Guanidine Salts, Infrastructure Services
AlzChem Group AG is a leading global supplier of specialty chemicals, operating through three distinct segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The companys diverse product portfolio caters to various industries, including chemical, food, animal feed, defence technology, and renewable energies. With a strong presence in Germany, the EU, and international markets, AlzChem has established itself as a key player in the specialty chemicals sector.
The Specialty Chemicals segment is a significant contributor to the companys revenue, with products such as composite materials, adhesives, and silicon nitride for ceramics being used in various applications. Additionally, the segment manufactures photovoltaic modules for the solar industry, capitalizing on the growing demand for renewable energy solutions. The Basics & Intermediates segment produces raw materials for specialty chemicals, as well as products for agriculture and metallurgy, further diversifying the companys revenue streams.
AlzChems product offerings are marketed under various brands, including CALCIUM CYANAMIDE PERLKA, CREAPURE, and DYHARD, among others. The companys strong brand presence and diverse product portfolio enable it to maintain a competitive edge in the market. With a history dating back to 1908, AlzChem has established a strong foundation in the specialty chemicals industry, with a global customer base and a commitment to innovation and quality.
Analyzing the technical data, we can see that the stock has been trending upwards, with a current price of 137.00 EUR, which is also its 52-week high. The SMA20, SMA50, and SMA200 are all trending upwards, indicating a strong bullish sentiment. The ATR of 5.35 EUR suggests a moderate level of volatility. Based on the technical indicators, we can forecast a potential price target of 145.00 EUR in the short term, driven by the ongoing bullish trend.
From a fundamental perspective, AlzChems market capitalization stands at 1301.33M EUR, with a P/E ratio of 23.10 and a forward P/E of 21.60. The companys RoE of 28.25% indicates a strong ability to generate returns on equity. Considering the fundamental data, we can forecast a potential earnings growth of 10-15% in the next fiscal year, driven by the companys diversified product portfolio and growing demand for specialty chemicals. This, combined with the technical indicators, suggests a potential long-term price target of 170.00 EUR.
Additional Sources for ACT Stock
ACT Stock Overview
Market Cap in USD | 1,520m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Specialty Chemicals |
IPO / Inception |
ACT Stock Ratings
Growth Rating | 82.7 |
Fundamental | 87.0 |
Dividend Rating | 75.1 |
Rel. Strength | 183 |
Analysts | - |
Fair Price Momentum | 164.23 EUR |
Fair Price DCF | 209.49 EUR |
ACT Dividends
Dividend Yield 12m | 1.89% |
Yield on Cost 5y | 10.56% |
Annual Growth 5y | 9.86% |
Payout Consistency | 94.6% |
Payout Ratio | 120.8% |
ACT Growth Ratios
Growth Correlation 3m | 92.9% |
Growth Correlation 12m | 96% |
Growth Correlation 5y | 60.3% |
CAGR 5y | 49.55% |
CAGR/Max DD 5y | 1.26 |
Sharpe Ratio 12m | -0.09 |
Alpha | 169.93 |
Beta | 0.140 |
Volatility | 42.85% |
Current Volume | 9.9k |
Average Volume 20d | 26.7k |
As of June 26, 2025, the stock is trading at EUR 131.40 with a total of 9,933 shares traded.
Over the past week, the price has changed by -2.95%, over one month by +8.60%, over three months by +41.77% and over the past year by +182.34%.
Yes, based on ValueRay´s Fundamental Analyses, AlzChem (XETRA:ACT) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.96 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACT is around 164.23 EUR . This means that ACT is currently undervalued and has a potential upside of +24.98% (Margin of Safety).
AlzChem has no consensus analysts rating.
According to our own proprietary Forecast Model, ACT AlzChem will be worth about 177.8 in June 2026. The stock is currently trading at 131.40. This means that the stock has a potential upside of +35.27%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 117.4 | -10.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 177.8 | 35.3% |